Profile data is unavailable for this security.
About the company
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
- Revenue in HKD (TTM)3.41bn
- Net income in HKD1.21bn
- Incorporated2020
- Employees1.05k
- LocationSciClone Pharmaceuticals (Holdings) Ltd22/FCentral Plaza, 381 Middle Huaihai RoadSHANGHAI ChinaCHN
- Websitehttps://www.sciclone.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Everest Medicines Ltd | 136.23m | -913.55m | 7.91bn | 432.00 | -- | 1.45 | -- | 58.04 | -2.92 | -2.92 | 0.4352 | 16.83 | 0.0203 | 2.25 | 4.57 | 315,358.20 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 8.71bn | 798.00 | 16.11 | 2.25 | 12.93 | 5.71 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Lepu Biopharma Co Ltd | 243.79m | -23.90m | 8.75bn | 429.00 | -- | 9.01 | 112.08 | 35.87 | -0.0144 | -0.0144 | 0.1469 | 0.5847 | 0.0917 | 1.06 | 1.62 | 568,271.50 | -1.23 | -- | -1.91 | -- | 87.45 | -- | -13.45 | -- | 0.7201 | 0.1388 | 0.4549 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| Cansino Biologics Inc | 373.42m | -1.60bn | 9.25bn | 1.49k | -- | 0.9243 | -- | 24.76 | -6.50 | -6.50 | 1.51 | 23.10 | 0.0332 | 2.37 | 0.4619 | 249,947.80 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| AIM Vaccine Co Ltd | 1.28bn | -1.41bn | 9.72bn | 1.62k | -- | 2.47 | -- | 7.57 | -1.16 | -1.16 | 1.06 | 3.25 | -- | -- | -- | 791,020.30 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| InnoCare Pharma Ltd | 798.96m | -682.91m | 9.79bn | 1.09k | -- | 1.14 | -- | 12.25 | -0.4049 | -0.4049 | 0.4735 | 4.39 | 0.073 | 1.39 | 3.39 | 733,662.20 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Shanghai Henlius Biotech Inc | 5.84bn | 590.69m | 9.89bn | 3.64k | 16.79 | 4.17 | 10.10 | 1.69 | 1.08 | 1.08 | 10.69 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,604,695.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.81bn | 2.16bn | 10.40bn | 4.62k | 4.83 | 1.21 | 4.28 | 1.53 | 2.45 | 2.45 | 7.74 | 9.76 | 0.5111 | 3.62 | 4.09 | 1,474,568.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Keymed Biosciences Inc | 383.06m | -388.76m | 10.64bn | 897.00 | -- | 3.29 | -- | 27.79 | -1.49 | -1.49 | 1.45 | 11.55 | 0.0906 | 0.7314 | 26.14 | 427,050.40 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Luye Pharma Group Ltd | 6.65bn | 576.18m | 11.17bn | 5.27k | 19.29 | 0.8241 | 8.32 | 1.68 | 0.1539 | 0.1539 | 1.78 | 3.60 | 0.247 | 2.42 | 3.60 | 1,261,035.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.47bn | 1.05k | 9.79 | 3.12 | 8.36 | 3.36 | 1.86 | 1.86 | 5.25 | 5.85 | 0.7585 | 3.56 | 3.83 | 3,251,220.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 14.49bn | 5.60k | 11.02 | 2.09 | 8.29 | 2.24 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Simcere Pharmaceutical Group Ltd | 7.15bn | 773.24m | 14.80bn | 7.03k | 19.55 | 1.90 | 13.36 | 2.07 | 0.2901 | 0.2901 | 2.74 | 2.99 | 0.6106 | 3.53 | 2.65 | 1,017,277.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
Data as of May 17 2024. Currency figures normalised to SciClone Pharmaceuticals (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD
7.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 13.34m | 2.13% |
| Zhong Geng Fund Management Co. , Ltd.as of 30 Jun 2023 | 10.58m | 1.69% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 9.04m | 1.44% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 2.98m | 0.48% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 2.29m | 0.37% |
| Manulife TEDA Fund Management Co., Ltd.as of 30 Jun 2023 | 1.85m | 0.29% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 1.60m | 0.26% |
| Cambria Investment Management LPas of 04 Apr 2024 | 1.60m | 0.26% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 1.33m | 0.21% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 1.08m | 0.17% |
More ▼
Data from 30 Jun 2023 - 02 May 2024Source: FactSet Research Systems Inc.
